Osteoporosis in patients taking selective serotonin reuptake inhibitors: a focus on fracture outcome

@article{Bruyre2014OsteoporosisIP,
  title={Osteoporosis in patients taking selective serotonin reuptake inhibitors: a focus on fracture outcome},
  author={O. Bruy{\`e}re and J. Reginster},
  journal={Endocrine},
  year={2014},
  volume={48},
  pages={65-68}
}
  • O. Bruyère, J. Reginster
  • Published 2014
  • Medicine
  • Endocrine
  • Depression is one of the most important mental health problems and a leading cause of disability. Selective serotonin reuptake inhibitors (SSRIs) are considered as first-line therapy for the treatment of depressive symptoms among older adults because of their presumed favorable adverse effect profile. However, they could have deleterious effects on the bone. Evidence from longitudinal, cross-sectional, and prospective cohort studies suggests that the use of antidepressants at therapeutic doses… CONTINUE READING
    Drug-induced bone loss: a major safety concern in Europe
    • 9

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 47 REFERENCES
    Antidepressant medications and osteoporosis.
    • 110
    SSRIs, bone mineral density, and risk of fractures — a review
    • 32